ESR1 and ovarian carcinoma: Consistent with BHPI acting through ERα, BHPI did not inhibit proliferation or restore paclitaxel sensitivity in ERα negative MDR1 overexpressing NIH/ADRes ovarian cancer cells (Supplementary Figure 5B).